Christopher Downs - 17 Nov 2025 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Role
Chief Financial Officer
Signature
/s/ Christopher Downs
Issuer symbol
CNSP
Transactions as of
17 Nov 2025
Transactions value $
$0
Form type
4
Filing time
19 Nov 2025, 17:00:02 UTC
Previous filing
10 Apr 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Downs Christopher Chief Financial Officer C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH, SUITE 900, HOUSTON /s/ Christopher Downs 19 Nov 2025 0001705978

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNSP Option to purchase common stock Award $0 +4.88K $0.00 4.88K 17 Nov 2025 Common Stock 4.88K $30.00 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on March 11, 2025 (the "Grant Date"), subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025.
F2 The options set forth in the table vest as follows: 50% on the six-month anniversary of the Grant Date, 25% on the 12-month anniversary of the Grant Date, and 25% on the 18-month anniversary of the Grant Date, subject to the reporting person's continued employment on each vesting date.
F3 Issued in connection with the reporting person's employment with the Company.